Jove
Visualize
Contact Us

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

42
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
42
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

528
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

36
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
36
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

149
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
149
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

751
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
751

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing short- and long-term outcomes of transcatheter valve-in-valve versus redo surgical aortic valve replacement: a literature review.

Journal of cardiothoracic surgery·2026
Same author

Scoping Out Concomitant Coronary Artery Disease Management in Transcatheter Aortic Valve Replacement Recipients.

JAMA network open·2025
Same author

The prognostic value of N-terminal pro-B-type natriuretic peptide in patients with severe aortic stenosis and preserved ejection fraction.

Progress in cardiovascular diseases·2025
Same author

Corrigendum to 'High-Definition Intravascular Ultrasound Versus Optical Coherence Tomography: Lumen Size and Plaque Morphology' [Journal of the Society for Cardiovascular Angiography & Interventions; 4 (2025) 102520].

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Frailty Predicts Geriatric and Cardiovascular Adverse Outcomes After TAVR: A 5-Year Real-World Analysis.

JACC. Advances·2025
Same author

Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2025
Same journal

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same journal

Viability testing for guiding revascularization in ischemic cardiomyopathy.

Current opinion in cardiology·2026
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Novel devices for managing heart failure.

Travis Howard1, Nikolaos Spilias, Sanjeeb Bhattacharya

  • 1Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Current Opinion in Cardiology
|May 25, 2022
PubMed
Summary
This summary is machine-generated.

Novel device-based therapies show promise for treating heart failure (HF) when optimal medical therapy is insufficient. Minimally invasive interventions aim to improve outcomes for patients with this complex cardiovascular condition.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K

Related Experiment Videos

Last Updated: Sep 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K

Area of Science:

  • Cardiovascular Medicine
  • Medical Devices
  • Interventional Cardiology

Background:

  • Heart failure (HF) remains a significant cause of morbidity, mortality, and healthcare costs despite therapeutic advances.
  • Many patients with HF experience persistent symptoms even with optimal medical management, highlighting an unmet clinical need.
  • The increasing prevalence of HF necessitates the exploration of innovative treatment strategies.

Purpose of the Study:

  • To review the rationale, development, and current data for novel device-based therapies in heart failure.
  • To explore minimally invasive, device-based approaches to address the treatment gap in acute and chronic HF.
  • To summarize emerging transcatheter interventions for structural heart disease applied to HF management.

Main Methods:

  • Review of recent studies and ongoing pivotal trials on device-based HF therapies.
  • Analysis of interventions altering left ventricular geometry (ventriculoplasty).
  • Evaluation of devices creating left atrial decompression shunts and modulating blood flow.

Main Results:

  • Emerging device therapies have demonstrated safety and efficacy in preliminary studies.
  • Interventions include ventriculoplasty, left atrial decompression shunts, and vena caval/renal blood flow modulation.
  • Large-scale clinical outcome trials are currently underway to validate these findings.

Conclusions:

  • Device-based therapies represent a promising frontier in managing the complex and heterogeneous syndrome of heart failure.
  • These innovative approaches may expand treatment options for patients with refractory HF symptoms.
  • Minimally invasive strategies hold potential to bridge the gap in current HF treatment paradigms.